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Long-Term Insulin Requirement After Liver Transplantation With 
FK 506 in American Veterans 
J. Tabasco-Minguillan, L. Mieles, P. Carroll, J. Gavaler, D.H. Van Thiel, and T.E. Starzl 
FK 506 is a new immunosuppressive drug that has been 
used with success in orthotopic liver transplantation 
(OLT).l-s The frequency-of onset of diabetes mellitus in 
nondiabetic patients folloWing OLT with cyclosporioe 
(CyA) has been reported to be 17.5%.2 With the advent of 
FK 506 as a potent immunosuppressive drug much atten-
tion has been paid to its diabetogenic effects. In previous 
studies, the incidence of new onset diabetes requiring 
insulin has been estimated to be 15% in adults and 3% in 
children following liver transplantation with FK 506.&-8 
The long-term effects of FK 506 in glucose metabolism and 
the need for insulin therapy after 0 L T with FK 506 are not 
known. The aim of the present study was to determine the 
long-term effects of FK 506 in the glucose metabolism and 
the need for insulin therapy after liver transplantation 
under primary FK 506 immunosuppression. 
PATIENTS AND METHODS 
From October 22, 1989 to December 31, 1991, a total of 52 
consecutive liver transplants were performed in 46 American 
veterans using primary FK 506 and steroid immunosuppression at 
the Pittsburgh Veterans Administration Medical Center. The 
patients were all males; 84% were white, 11% were black, and 5% 
were Hispanic. Mean age was 47 ± 9.3 years (range 28 to 67 
years). 
Immunosuppression 
The first seven patients received 0.15 mg/kg of FK 506 IV over 4 
hours, and then 0.075 mg/kg IV every 12 hours until able to take 
oral medication. The remaining patients received 0.1 mg/kg as a 
continuous drip over 24 hours, until able to take oral medication. 
The oral dose in both groups was 0.15 mg/kg every 12 hours. Dose 
adjustments were made according to the clinical course. 
All patients received 1 g of methylprednisolone immediately 
after revascularization of the graft. In the first seven patients this 
was followed by a taper from 200 mg to 20 mg over 5 days. The 
remaining patients were given 20 mg of IV methylprednisolone 
immediately after transplantation and daily thereafter (20 mg of 
prednisone as soon as they were able to have oral intake). 
Thereafter, the dose of prednisone was tapered as much as the 
graft function permitted. 
Diagnostic Analysis 
The plasma glucose and FK 506 levels were recorded before liver 
transplantation and at 7 days, and 1, 3, 6, 12, 18, and 24 months 
following OLT. FK 506 plasma levels were determined with the 
enzyme immunoassay technique of Tamura et aI.9 The glucose 
determinations were made using standard colorimetric methods. 
The daily doses of FK 506 and prednisone being used were 
recorded at 7 days and at 1,3, 6, 12, 18, and 24 months post-OL T. 
In addition, the need for outpatient insulin therapy or oral medi-
cation to correct hyperglycemia was recorded at 3, 6, 12, 18, and 
24 months following liver transplantation. Patient and graft sur-
vival were recorded at 6, 12, and 24 months. 
RESULTS 
Mean follow-up was 367 ± 74 days (range 28 to 803 days). 
The actuarial patient survival was 93% at 6 months, and 
89% at 12 months and 24 months. Graft survival was 84%, 
81%, and 72% respectively. Three patients died in the 
perioperative period «3 months), and one patient died at 
10 months postoperatively. None of the patients died from 
complications of uncontrolled diabetes. Seven patients 
(13.6%) were diabetic before OLT, four (7.7%) had insulin-
dependent diabetes mellitus (IDDM) , and three (5.7%) 
were non-IDDM. All four pre-OLT IDDM patients contin-
ued to require insulin post-OLT. Of the three pre-OLT 
non-IDDM patients, two required insulin at 6 and 12 
months of follow-up, and one continued to require oral 
hypoglycemic medication. Seven patients (13.6%) who 
were not diabetics pre-OLT had required outpatient insulin 
therapy post-OLT. Three patients required temporary 
insulin therapy during the first three post-OLT months; 
one of them is currently on an oral hypoglycemic medica-
tion, and two have become normoglycemic on no addi-
tional therapy. The number of patients requiring outpatient 
insulin therapy at 3, 6, 12, 18, and 24 months post-OLT 
was 9 of 40, 8 of 30, 2 of 18, 0 of 10, and 0 of 5, 
respectively. Of these, the number of patients who re-
quired insulin for the first time was 6 of 40, 6 of 30, 1 of 18, 
o of 10, and 0 of 5 at the same time points post-OLT. There 
seemed to be no relation between the dose of FK 506 being 
used and the need for long-term insulin therapy in any of 
these patients, including those who became diabetics. 
Figure I shows the plasma levels of glucose and FK 506 
post-OLT in all 46 patients. 
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Fig 1. Serum FK 506 and glucose levels following liver trans-
plantation in 46 veterans, 
DISCUSSION 
A diabetogenic effect of FK 506 has been observed both in 
in vitro and in vivo work in animals as well as in in vivo 
studies in humans. In children, the frequency of develop-
ing new onset insulin requiring diabetes with primary FK 
506 immunosuppression after OLT is <2% and somewhat 
higher (7%) in the setting of FK 506 rescue.7 In adults, oral 
glucose tolerance tests have been shown to be abnormal in 
12 liver transplant recipients whose immunosuppression 
consisted of FK 506 and low dose prednisone. 1O The 
short-term diabetogenic effect of FK 506 in adults follow-
ing liver transplantation is a well-known occurrence. J J The 
present study represents the first report of the long-term 
incidence of insulin requirement after OLT with primary 
FK 506 immunosuppression. We selected 3 months as our 
first follow-up point since many of these patients remain 
hospitalized in the perioperative period and are receiving 
medical therapy (hyperalimentation, immunosuppressive 
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agents other than FK 506, etc) which is likely to cause 
hyperglycemia. The prevalence of insulin requirement 
with FK 506 decreased after 6 to 12 months post-OLT, 
with no new cases occurring after 12 months. suggesting a 
dependence on the amount of steroids received. In addi-
tion, the fact that some patients required insulin only 
temporarily could indicate a reversible diabetogenic effect 
of FK 506. The dose and plasma levels of FK 506 seen in 
the diabetic patients were similar to the nondiabetics, 
indicating an intrinsic diabetogenic action that may be dose 
independent. None of the patients died of complications of 
uncontrolled diabetes. 
In summary, the need for de novo insulin therapy at 3, 6, 
and 12 months post-OLT with FK 506 was 15%,20%, and 
5.5%, respectively, with no new post-OLT IDDM patients 
at 18 and 24 months. A requirement for insulin therapy did 
not affect long-term graft or patient survival. The need for 
insulin therapy post-OLT was independent of the dose of 
FK 506 being utilized to prevent graft rejection. 
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